Laura Lee Dupuis

Laura Lee Dupuis

Auto-generated profile, based on publicly available information

Laura Lee Dupuis

Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2013 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Jennifer StinsonJennifer Stinson
Jennifer Stinson
LJLindsay A Jibb
Lindsay A Jibb
CNCynthia Nguyen
Cynthia Nguyen
Paul NathanPaul Nathan
Paul Nathan
AMAnne Marie Maloney
Anne Marie Maloney
MOMike Orr
Mike Orr
Development and Testing of a Multidimensional iPhone Pain Assessment Application for Adolescents with Cancer

20 March 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Thomas LehrnbecherThomas Lehrnbecher
Thomas Lehrnbecher
PRPaula D. Robinson
Paula D. Robinson
RARoland A. Ammann
Roland A. Ammann
BFBrian Fisher
Brian Fisher
PPPriya Patel
Priya Patel
LSLillian Sung
Lillian Sung
PURPOSE: To update a clinical practice guideline (CPG) for the empiric management of fever and neutropenia (FN) in pediatric patients with cancer and hematopoietic cell transplantation recipients. METHODS: The International Pediatric Fever and Neutropenia Guideline Panel reconvened to conduct the second update of this CPG. We updated the previous systematic review to identify new randomized controlled trials (RCTs) evaluating any strategy for the management of FN in pediatric patients. Using the Grading of Recommendations Assessment, Development and Evaluation framework, evidence quality was classified as high, moderate, low, or very low. The panel updated recommendations related to initial management, ongoing management, and empiric antifungal therapy. Changes from the 2017 CPG were articulated, and good practice statements were considered. RESULTS: We identified 10 new RCTs in addition to the 69 RCTs identified in previous FN CPGs to inform the 2023 FN CPG. Changes from the 2017 CPG included two conditional recommendations regarding (1) discontinuation of empiric antibacterial therapy in clinically well and afebrile patients with low-risk FN if blood cultures remain negative at 48 hours despite no evidence of marrow recovery and (2) pre-emptive antifungal therapy for invasive fungal disease in high-risk patients not receiving antimold prophylaxis. The panel created a good practice statement to initiate FN CPG-consistent empiric antibacterial therapy as soon as possible in clinically unstable febrile patients. CONCLUSION: The updated FN CPG incorporates important modifications on the basis of recently published trials. Future work should focus on addressing knowledge gaps, improving CPG implementation, and measuring the impact of CPG-consistent care.

23 November 2015 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
FSFurqan Shaikh
Furqan Shaikh
LDL. Lee Dupuis
L. Lee Dupuis
SASarah Alexander
Sarah Alexander
AGAbha Gupta
Abha Gupta
LMLuc Mertens
Luc Mertens
Paul NathanPaul Nathan
Paul Nathan
Background: Several randomized controlled trials (RCTs) have demonstrated that dexrazoxane reduces anthracycline cardiotoxicity in adults, but use in children has been hindered by lack of direct evidence of cardioprotection and concerns regarding second malignant neoplasms (SMNs). This study aimed to systematically review the evidence regarding dexrazoxane in children. Methods: We searched Medline, Embase, the Cochrane Library, and abstracts for RCTs and nonrandomized studies (NRSs) that compared dexrazoxane to no cardioprotection among children. We combined findings using random-effects models. All statistical tests were two-sided. Results: Eleven eligible publications reported results from five RCTs (1254 patients), and 15 publications reported results from 12 NRSs (3385 patients). Dexrazoxane did not impact clinical cardiotoxicity in RCTs because of a low cardiotoxic event rate (three events among all patients) but was associated with a reduction in subclinical cardiotoxicity. Among NRSs, dexrazoxane was associated with a reduction in clinical cardiotoxicity (relative risk (RR) = 0.29, P = .001) and clinical+subclinical cardiotoxicity (RR = 0.43, P < .001). Among RCTs, 17 of 635 (2.7%) patients treated with dexrazoxane developed an SMN compared with seven of 619 (1.1%) who did not receive dexrazoxane (RR = 2.37, P = .06). Two RCTs that used concurrent etoposide reported an increased risk of acute myeloid leukemia, while one that used cranial radiation reported an increased risk of brain tumors. Event-free survival did not differ (P = .91). Conclusion: Dexrazoxane is associated with a statistically significant risk reduction for most cardiotoxic outcomes. Dexrazoxane is associated with a statistically borderline increase in SMNs, possibly because of an interaction with concurrent cancer therapies. The decision to use dexrazoxane in children should balance the risks of cardiotoxicity and SMNs specific to each treatment protocol.

2 November 2019 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
TLThomas Lehrnbecher
Thomas Lehrnbecher
BFBrian T Fisher
Brian T Fisher
BPBob Phillips
Bob Phillips
SASarah Alexander
Sarah Alexander
RARoland A Ammann
Roland A Ammann
LSLillian Sung
Lillian Sung
Background: Bacteremia and other invasive bacterial infections are common among children with cancer receiving intensive chemotherapy and in pediatric recipients of hematopoietic stem cell transplantation (HSCT). Systemic antibacterial prophylaxis is one approach that can be used to reduce the risk of these infections. Our purpose was to develop a clinical practice guideline (CPG) for systemic antibacterial prophylaxis administration in pediatric patients with cancer and those undergoing HSCT.Methods: An international and multidisciplinary panel was convened with representation from pediatric hematology/oncology and HSCT, pediatric infectious diseases (including antibiotic stewardship), nursing, pharmacy, a patient advocate, and a CPG methodologist. The panel used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to generate recommendations based on the results of a systematic review of the literature.Results: The systematic review identified 114 eligible randomized trials of antibiotic prophylaxis. The panel made a weak recommendation for systemic antibacterial prophylaxis for children receiving intensive chemotherapy for acute myeloid leukemia and relapsed acute lymphoblastic leukemia (ALL). Weak recommendations against the routine use of systemic antibacterial prophylaxis were made for children undergoing induction chemotherapy for ALL, autologous HSCT and allogeneic HSCT. A strong recommendation against its routine use was made for children whose therapy is not expected to result in prolonged severe neutropenia. If used, prophylaxis with levofloxacin was recommended during severe neutropenia.Conclusions: We present a CPG for systemic antibacterial prophylaxis administration in pediatric cancer and HSCT patients. Future research should evaluate the long-term effectiveness and adverse effects of prophylaxis.

1 February 2020 in The Lancet Child & Adolescent Health
Verified
Journal Article
Closed access
DFDavid R Freyer
David R Freyer
PBPenelope R Brock
Penelope R Brock
KCKay W Chang
Kay W Chang
LDL Lee Dupuis
L Lee Dupuis
SESidnei Epelman
Sidnei Epelman
LSLillian Sung
Lillian Sung

19 March 2013 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
LDL. Lee Dupuis
L. Lee Dupuis
SBSabrina Boodhan
Sabrina Boodhan
MHMark Holdsworth
Mark Holdsworth
PRPaula D. Robinson
Paula D. Robinson
RHRichard Hain
Richard Hain
LSLillian Sung
Lillian Sung
This guideline provides an approach to the prevention of acute antineoplastic‐induced nausea and vomiting (AINV) in children. It was developed by an international, inter‐professional panel using AGREE and CAN‐IMPLEMENT methods. Evidence‐based interventions that provide optimal AINV control in children receiving antineoplastic agents of high, moderate, low, and minimal emetogenicity are recommended. Recommendations are also made regarding selection of antiemetic agents for children who are unable to receive corticosteroids for AINV control, the role of aprepitant and optimal doses of antiemetic agents. Gaps in the evidence used to support the recommendations were identified. The contribution of this guideline to AINV control in children requires prospective evaluation. Pediatr Blood Cancer 2013; 60: 1073–1082.